Hydrocodone

Hydrocodone, also known chemically as dihydrocodeinone, is a semisynthetic opioid produced from the opium poppy alkaloids codeine and thebaine ^[3]. It belongs to the same broad family of drugs as morphine and oxycodone and is used primarily as an analgesic for pain and as an antitussive to control cough ^[1]. Because it is not extracted directly from the poppy but chemically modified from natural precursors, it is classified as semisynthetic; researchers have even engineered yeast to build hydrocodone from sugar as a proof-of-concept alternative to poppy farming ^[3].

The compound was first synthesized in Germany in the early 1920s and later introduced into medical practice, receiving regulatory approval in the United States in the 1940s ^[3]. Over the following decades it became one of the most widely prescribed medications in the United States, which at one point accounted for the overwhelming majority of global hydrocodone consumption ^[1]. Extended-release single-ingredient formulations were introduced more recently for the management of chronic pain.

Hydrocodone is most commonly encountered in combination products, where it is paired with a non-opioid pain reliever such as acetaminophen (in Vicodin and Norco) or ibuprofen (in Vicoprofen), and in cough preparations combined with agents like homatropine or chlorpheniramine ^[1]. Single-ingredient extended-release versions, marketed under names such as Zohydro ER and Hysingla ER, deliver the drug gradually for around-the-clock pain control. The combination products are generally intended for shorter-term relief of moderate to severe pain.

Hydrocodone is processed in the liver by cytochrome P450 enzymes; the enzyme CYP3A4 handles the major metabolic route, while CYP2D6 converts a portion of the drug into hydromorphone, a more potent opioid ^[1][2]. Because CYP2D6 activity varies widely between individuals owing to genetic differences, the extent of this conversion, and therefore a person's response and risk of side effects, can differ substantially ^[2]. These pharmacogenetic factors are one reason opioid effects are not uniform across patients, a consideration highlighted in palliative care and in cautions about opioid use during breastfeeding ^[2][4].

As a mu-opioid agonist, hydrocodone produces euphoria and carries a high potential for tolerance, physical dependence, and addiction, and it has been a significant contributor to the broader problem of prescription opioid misuse ^[4]. Its abuse liability is often compared with that of oxycodone, and research has examined how factors such as sex and metabolic differences influence patterns of use and adverse effects ^[4]. Reflecting these risks, hydrocodone products in the United States were reclassified from Schedule III to the more restrictive Schedule II in 2014, placing them among the most tightly controlled prescription medicines.

Common side effects mirror those of other opioids and include nausea, vomiting, constipation, drowsiness, dizziness, and lightheadedness ^[1]. The most dangerous risk is respiratory depression, a slowing or stopping of breathing that can be fatal in overdose, particularly when the drug is combined with alcohol, sedatives, or other central nervous system depressants ^[1]. Overdose can be reversed with the opioid antagonist naloxone, and when hydrocodone is combined with acetaminophen, exceeding recommended limits also carries a separate risk of liver injury from the acetaminophen component.

The dangerous edge with any opioid is respiratory depression; hydrocodone slows your breathing, and enough of it (especially stacked with alcohol, benzodiazepines, gabapentinoids, or other sedatives) can slow it to a stop. Everyday side effects are the usual opioid lineup; constipation that does not fade, nausea, drowsiness, itching, and lightheadedness. Used regularly it builds tolerance and physical dependence, so stopping abruptly brings a rough withdrawal (aches, sweats, gut cramps, anxiety, insomnia), and it carries real addiction potential. The sneaky second hazard lives in the combo products; the acetaminophen.

Hydrocodone on its own rarely hurts the liver, but acetaminophen overdose is a leading cause of acute liver failure, and it is easy to blow past the safe daily acetaminophen limit by taking extra combo pills or by pairing them with over-the-counter Tylenol. That is exactly why the FDA capped prescription combo products at 325 mg of acetaminophen per pill (asked in 2011, in force by 2014) and pulled the higher-acetaminophen versions.

Watch out for CYP3A4 inhibitors (some antifungals, certain antibiotics, grapefruit) which can raise hydrocodone levels, and serotonergic drugs which add a small serotonin-syndrome risk. Because of its abuse and dependence profile the US moved hydrocodone combination products from Schedule III to Schedule II in 2014; it is a controlled substance, and naloxone reverses an overdose if it is on hand.

Hydrocodone combined with selective serotonin reuptake inhibitors (SSRIs) significantly increases the risk of opioid overdose; a large cohort study found that initiating citalopram, escitalopram, fluoxetine, or paroxetine while already on hydrocodone raised overdose hospitalization risk 1.17 to 1.29-fold compared with sertraline, with sertraline appearing safer ^[5]. The mechanism involves both pharmacokinetic changes (certain SSRIs inhibit CYP2D6, which metabolizes hydrocodone) and pharmacodynamic effects (additive CNS depression). SSRIs other than sertraline showed similar increased risk; the exact reason sertraline conferred lower risk was not determined. The interaction with non-SSRI antidepressants, antihistamines, and antiemetics remains incompletely characterized.

Checking a whole stack? Run it through interactions + stacks.